{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:42:09Z","timestamp":1793472129884,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":2382,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We recently reported the frequent occurrence of polycystic ovaries and hyperandrogenism associated with weight gain and hyperinsulinemia in women taking valproate for epilepsy. The purpose of this study was to evaluate the risks related to valproate\u2010induced hyperinsulinemia and their reversibility after discontinuing the medication. Sixteen women with valproate\u2010related polycystic ovaries or hyperandrogenism participated in the study. Vaginal ultrasonography was performed, and endocrine and lipid parameters were measured. Thereafter, lamotrigine was substituted for valproate and the patients were observed for 12 months. Twenty\u2010four healthy age\u2010matched women served as control subjects. Twelve women completed the 12\u2010month follow\u2010up. While still on valproate they had centripetal obesity with associated hyper insulinemia and unfavorable serum lipid profiles. The body\u2010mass index and fasting serum insulin and testosterone concentrations decreased during the first year after replacing valproate with lamotrigine whereas the HDL\u2010cholesterol\/total cholesterol ratios increased from 0.17 \u00b1 0.06 to 0.26 \u00b1 0.05. The total number of polycystic ovaries in these women decreased from 20 during valproate medication to 11 one year after replacing valproate with lamotrigine. Valproate induces a metabolic syndrome with centripetal obesity, hyperinsulinemia lipid abnormalities, and polycystic ovaries\/hyperandrogenism in women with epilepsy. These valproate\u2010related risks can be reduced by substituting lamotrigine for valproate.<\/jats:p>","DOI":"10.1002\/ana.410430406","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T10:15:23Z","timestamp":1104574523000},"page":"446-451","source":"Crossref","is-referenced-by-count":272,"title":["Valproate, lamotrigine, and insulin\u2010mediated risks in women with epilepsy"],"prefix":"10.1002","volume":"43","author":[{"given":"Jouko I. T.","family":"Isoj\u00e4rvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"R\u00e4tty\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilho V.","family":"Myllyl\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Knip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto J.","family":"Pakarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydin","family":"Tekay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha S.","family":"Tapanainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311043291904"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390506"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1984.tb00804.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6291.577"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1016380"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.12.1595"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb02419.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447020-00008"},{"key":"e_1_2_1_11_2","first-page":"313","volume-title":"Epileptic syndromes in infancy, childhood and adolescence","author":"Wolf P","year":"1992"},{"key":"e_1_2_1_12_2","first-page":"889","volume-title":"Antiepileptic drugs","author":"Leach JP","year":"1995"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90581-2"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6543.355"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/39.4.578"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/clinchem\/24.6.931","article-title":"Cholesterol in high\u2010density lipoprotein: use of Mg2+ dextran sulfate in its enzymatic measurement","volume":"24","author":"Finely PR","year":"1978","journal-title":"Clin Chem"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90404-K"},{"key":"e_1_2_1_18_2","first-page":"S142","article-title":"Valproic acid (VPA) associated weight gain in monotherapy patients with epilepsy","volume":"35","author":"Gidal BE","year":"1994","journal-title":"Epilepsia"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.14.3.173"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109263251307"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7017.1401"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02295.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)53699-1"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509283331307"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1986.00520040029014"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1988.tb03770.x"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410430406","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410430406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T15:49:18Z","timestamp":1698508158000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410430406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1002\/ana.410430406"],"URL":"https:\/\/doi.org\/10.1002\/ana.410430406","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4]]}}}